After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.

Although patients with heart failure and preserved ejection fraction (HF-PEF) represent nearly half of the population with chronic heart failure, few evidence-based medical therapies are available. The neutral overall results of the TOPCAT trial of spironolactone in HF-PEF leave clinicians who treat heart failure with an ongoing clinical dilemma. In this review, we outline an approach to the clinical management of the patient with HF-PEF synthesizing data from available clinical trials and expert consensus.

[1]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[2]  R. McKelvie,et al.  History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[3]  W. Hundley,et al.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. , 2002, JAMA.

[4]  Sanjiv J. Shah,et al.  Association of Comorbidity Burden With Abnormal Cardiac Mechanics: Findings From the HyperGEN Study , 2014, Journal of the American Heart Association.

[5]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[6]  J. Berk,et al.  Transthyretin (TTR) Cardiac Amyloidosis , 2012, Circulation.

[7]  Peter Van Buren,et al.  Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin , 2015, Circulation.

[8]  M. Voskuil,et al.  Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial , 2013, European journal of heart failure.

[9]  M. Pfeffer,et al.  Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme , 2003, European journal of heart failure.

[10]  R. Nishimura,et al.  Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. , 2012, Journal of the American College of Cardiology.

[11]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[12]  V. Melenovský,et al.  Implications of coronary artery disease in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[13]  R. McKelvie,et al.  The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. , 2015, The Canadian journal of cardiology.

[14]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[15]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[16]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[17]  W. Edwards,et al.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.

[18]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[19]  Akshay S. Desai,et al.  Heart failure with recovered ejection fraction: a distinct clinical entity. , 2011, Journal of cardiac failure.

[20]  Sameer Ather,et al.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.

[21]  Sanjiv J. Shah,et al.  Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial. , 2015, Journal of cardiac failure.

[22]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights from DOSE-AHF and CARRESS-HF , 2015 .

[23]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[24]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[25]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[26]  Robert J Mentz,et al.  Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. , 2014, Journal of the American College of Cardiology.

[27]  D. Kass,et al.  Cardiac Structure and Ventricular–Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota , 2007, Circulation.

[28]  M. Brignole,et al.  Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. , 2011, European heart journal.

[29]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[30]  B. Borlaug,et al.  The pathophysiology of heart failure with preserved ejection fraction , 2014, Nature Reviews Cardiology.

[31]  S. Solomon,et al.  Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial , 2007, The Lancet.

[32]  Sanjiv J Shah,et al.  Heart failure with preserved ejection fraction: treat now by treating comorbidities. , 2008, JAMA.

[33]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[34]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[35]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[36]  R. Nishimura,et al.  The Hemodynamic Basis of Exercise Intolerance in Tricuspid Regurgitation , 2014, Circulation. Heart failure.

[37]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[38]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[39]  C. Lam,et al.  The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.

[40]  V. Roger,et al.  Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study , 2012, Circulation. Heart failure.

[41]  R. Nishimura,et al.  Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[42]  K. Shah,et al.  Transthyretin Cardiac Amyloidosis , 2017, Current Cardiology Reports.

[43]  Ali Ahmed,et al.  Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.

[44]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). , 2015, Circulation. Heart failure.

[45]  Alanna M. Chamberlain,et al.  Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction A Community-Based Study , 2013 .

[46]  V. Melenovský,et al.  Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. , 2015, Journal of the American College of Cardiology.

[47]  P. Ponikowski,et al.  Iron deficiency and cardiovascular disease , 2015, Nature Reviews Cardiology.

[48]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[49]  B. French,et al.  Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes , 2014, Circulation.

[50]  H. Krumholz,et al.  Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. , 2003, Journal of the American College of Cardiology.

[51]  Akshay S. Desai,et al.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. , 2011, American heart journal.

[52]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[53]  K. Weber.  Aldosterone in congestive heart failure. , 2001, The New England journal of medicine.

[54]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[55]  Gabriel A. Koepp,et al.  Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. , 2015, The New England journal of medicine.

[56]  Daniel Levy,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[57]  R. McKelvie,et al.  Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial , 2010, Circulation.

[58]  Sanjiv J. Shah,et al.  Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) , 2014, European journal of heart failure.

[59]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[60]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[61]  G. Biondi-Zoccai,et al.  Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). , 2014, The American journal of cardiology.

[62]  William T. Abraham,et al.  Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[63]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[64]  M. Zile,et al.  Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.